Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GLP-1 Therapy in Type 1 Diabetes: Evidence

A 2026 review weighs GLP-1-based therapy in type 1 diabetes against small tirzepatide and semaglutide trial safety signals.

Why we wrote this. A broad review can sound more settled than its small underlying trials. This readout keeps efficacy and ketone-related limits together.

In this article (4 sections)
  1. What the review adds
  2. The tirzepatide phase 2 signal
  3. Semaglutide showed a different kind of benefit
  4. What we don't yet know

A 2026 narrative review argues that GLP-1-based medicines may help selected adults who have type 1 diabetes plus overweight or obesity, but it also puts the safety problem in plain view: any reduction in insulin must avoid hypoglycemia without leaving too little insulin to suppress ketone production[1]. The review covers liraglutide, semaglutide, and tirzepatide. It is not a new trial or a treatment guideline.

Two small randomized trials help explain why the balance remains unsettled. One tested tirzepatide for 12 weeks in 24 adults with type 1 diabetes and obesity. Another tested semaglutide alongside automated insulin delivery in 28 adults, with 24 completing the crossover trial[2][3]. Both produced favorable efficacy signals, yet neither can establish long-term safety or routine use across the much broader type 1 diabetes population.

What the review adds

The indexed review is a narrative synthesis, meaning the authors selected and interpreted existing evidence rather than pooling every study through a prespecified meta-analysis. Its central question is not simply whether weight or insulin requirements change. It asks which patients might have a favorable benefit-risk balance and how safety concerns alter interpretation[1].

Earlier liraglutide trials reported lower body weight and insulin requirements but also raised concerns about hypoglycemia and ketosis. Newer semaglutide and tirzepatide reports renewed interest because the reviewed results include larger changes in weight and insulin dose. The review warns that gastrointestinal symptoms can reduce carbohydrate intake or cause dehydration, further complicating insulin management and ketone risk[1].

This is specific to type 1 diabetes. Insulin remains essential because the pancreas does not supply enough of it. A medicine that lowers appetite, food intake, or insulin requirements does not replace that biological need. Readers can use our tirzepatide evidence page and semaglutide evidence page for broader molecule context, but neither page turns an adjunctive research finding into self-treatment guidance.

The tirzepatide phase 2 signal

The tirzepatide trial randomized 24 adults aged 18 to 60 with type 1 diabetes and a body mass index of at least 30 kg/m². It was double-blind and placebo-controlled at one Australian site. Twenty-two participants completed 12 weeks. Weight was the primary endpoint[2].

Mean weight change was minus 10.3 kg with tirzepatide and minus 0.7 kg with placebo. The estimated treatment difference was minus 8.7 kg, equivalent to an 8.8% reduction during the study period. The trial also reported a placebo-adjusted HbA1c difference of minus 0.4 percentage points and a larger reduction in total daily insulin use[2]. These outcomes came from a small, short study and should not be treated as forecasts for an individual.

No diabetic ketoacidosis, severe hypoglycemia, or serious adverse events occurred in the tirzepatide trial. That reassuring observation is limited by sample size and duration. Nonserious adverse events were reported in 75% of the tirzepatide group and 8.3% of the placebo group, with gastrointestinal symptoms most common. Nausea was reported by half of those assigned tirzepatide[2]. A 24-person trial cannot reliably measure uncommon harms.

Semaglutide showed a different kind of benefit

The semaglutide study used a randomized crossover design, so participants received semaglutide and placebo in separate periods. After dose titration, each period included four weeks with automated insulin delivery. The primary outcome was time spent in the target glucose range, not weight[3].

Compared with placebo, semaglutide increased time in the target range by a mean 4.8 percentage points. Time below the two prespecified low-glucose thresholds did not significantly increase. No diabetic ketoacidosis or severe hypoglycemia occurred, but two recurrent episodes of euglycemic ketosis without acidosis were recorded during semaglutide use[3]. That safety detail supports the review's warning that glucose values alone may not capture every ketone-related risk.

The studies should not be blended into a single drug ranking. They tested different molecules, designs, endpoints, and treatment contexts. The tirzepatide trial centered on 12-week weight change in adults with obesity. The semaglutide crossover trial centered on glucose time in range during automated insulin delivery. Neither directly compared tirzepatide with semaglutide[2][3].

What we don't yet know

Longer studies are needed to establish whether the reported weight and glucose changes persist and how often serious safety events occur. The available randomized samples were small. Eligibility criteria also excluded several higher-risk situations, so trial safety cannot be assumed for people who would not have qualified. Evidence for adolescents, people without obesity, and those with recent severe events remains especially limited.

The review's proposed phenotype-directed approach is an expert interpretation, not proof that researchers can already identify every suitable patient. It calls for careful selection, individualized insulin adjustment, glucose and ketone monitoring, and structured education[1]. Those are clinical responsibilities. They should not be converted into a do-it-yourself insulin reduction protocol.

For now, the evidence supports a cautious conclusion: adjunctive GLP-1-based therapy is an active research area in type 1 diabetes, with measurable efficacy signals and unresolved safety questions. Anyone with type 1 diabetes considering a change to insulin or an added medicine needs specialist diabetes care. Abrupt insulin reduction can be dangerous even when glucose appears acceptable.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Are GLP-1 medicines approved to replace insulin in type 1 diabetes?

No. The reviewed evidence concerns adjunctive use alongside insulin. Type 1 diabetes still requires insulin, and the studies do not support replacing it with a GLP-1-based medicine.

What did the tirzepatide phase 2 trial find?

In 24 randomized adults with type 1 diabetes and obesity, tirzepatide produced greater 12-week weight loss than placebo. The study was too small and short to settle long-term safety.

What safety concern did the semaglutide trial identify?

No diabetic ketoacidosis or severe hypoglycemia occurred, but two episodes of recurrent euglycemic ketosis without acidosis were recorded during semaglutide use.

Can someone reduce insulin after starting a GLP-1 medicine?

Insulin changes in type 1 diabetes require specialist oversight. Too much reduction can permit ketone production, while too little adjustment may contribute to hypoglycemia as food intake and insulin needs change.

Sources

  1. [1]Rossatto et al. GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection. Diabetes Obes Metab. 2026. PMID 42946972.Tier 2 · expert↩
  2. [2]Snaith et al. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Trial. Diabetes Care. PMID 41264593. Full text in PMC.Tier 1 · primary↩
  3. [3]Pasqua et al. Weekly semaglutide with automated insulin delivery in type 1 diabetes: randomized crossover trial. Nature Medicine. PMID 39794615. Full text in PMC.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars